7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8 Purity >98.0% (HPLC) Brexpiprazole Intermediate Factory

Name: 7-(4-Chlorobutoxy)quinolin-2(1H)-one  CAS: 913613-82-8 Purity: >98.0% (HPLC)  Appearance: Pale Yellow to Pale Beige Solid Intermediate of Brexpiprazole (CAS: 913611-97-9) E-Mail: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moistureRuifu Chemical Supply Brexpiprazole Intermediates Brexpiprazole CAS 913611-97-9 7-Hydroxyquinolinone CAS 70500-72-0 4-Bromobenzo[b]thiophene CAS 5118-13-8 1-(1-Benzothiophen-4-yl)piperazine Hydrochloride CAS 913614-18-3 7-(4-Chlorobutoxy)quinolin-2(1H)-one CAS 913613-82-8 4-Chlorobenzo[b]thiophene CAS 66490-33-3
Item Specifications
Appearance Pale Yellow to Pale Beige Solid
Purity / Analysis Method >98.0% (HPLC)
Infrared Spectrum Conforms to Structure
NMR  Conforms to Structure
Test Standard Enterprise Standard
Usage Intermediate / Impurity of Brexpiprazole (CAS: 913611-97-9)

Description:

Specifications:

Package & Storage:

Chemical Name 7-(4-Chlorobutoxy)quinolin-2(1H)-one
Synonyms 7-(4-Chlorobutoxy)-1H-Quinolin-2-one; Brexpiprazole Impurity 23 
CAS Number 913613-82-8
CAT Number RF-PI1980
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C13H14ClNO2
Molecular Weight 251.71
Boiling Point 460.8±45.0℃
Density  1.216±0.06 g/cm3
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

7-(4-Chlorobutoxy)quinolin-2(1H)-one (CAS: 913613-82-8) is an intermediate / impurity of Brexpiprazole (CAS: 913611-97-9). Brexpiprazole is an atypical antipsychotic drug. It is a D2 dopamine partial agonist called serotonin-dopamine activity modulator (SDAM). The drug received FDA approval on July 13, 2015 for the treatment of schizophrenia, and as an adjunctive treatment for depression. Although Brexpiprazole failed Phase II clinical trials for ADHD, Brexpiprazole has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours